Recently, our President and Managing Director, Jennifer Che, participated as a speaker at the HKSTP Market Discovery - BIO Connect event, hosted by HKSTP and InvestHK. This exclusive gathering brought together international biotech disruptors, offering them valuable insights into accessing the vast markets of Asia and beyond.

In her talk titled "Biotech Disruptors Benefit from HK IP," Jennifer highlighted the unique advantages Hong Kong offers from an intellectual property perspective. She discussed the rapidly developing IP ecosystem, including the homegrown original grant patent system and various tax and funding incentives that make the region an attractive hub for research and development. Additionally, she emphasized the expertise of local firms like Eagle IP, which are adept at navigating the complex IP challenges within the Greater Bay Area.

我們過去活動

Recommended Insights

Can Post Filing Data Overcome Inventive Step in China?

2018年11月19日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

The Latest on Post-Filing Data in China’s Patent Law

2020年4月29日
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]
Top crossarrow-right